||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Real-Time news about Lipoxen (London Stock Exchange): 0 recent articles
|the_doctor: buywell, you really are a TRUE [email protected]!
I posted here early today saying that I thought the refinancing was a good result
rather than just take the compliment from an honourable man, you instead decided to go posting silly deramping, gloating charts across several threads.
You really are a vile character
I was perfectly happy to be positive about Lipoxen's deal, but you know what?
Maybe the Lipoxen share price is now going to get hammered as shareholders in the acquired company dump to get what they can?
There are presumably no deals pending, since if there were, Lipoxen would have hung on and got better prices
Just as you've been gloatingly saying 'looks like charts are right'
Well, I guess they are buywell
millions of shares dumped will see the share price hit 6p
IF LIPOXEN's TECH IS ANY GOOD, WHY BUY ANOTHER DIFFERENT COMPANY
MASSIVE OVERHANG AT 11p - 110m shares placed!
SymbioTec HOLDERS WILL LIKELY WANT AN EXIT - THAT'S 80m shares to come onto the market
OH and LOOK
Two can play at your game buywell
YET AGAIN, you went out of your way to deramp, even after I posted only a positive comment on here|
|the_doctor: 'I will let others speak on my behalf ...'
because you cant justify the fact that totally unprovoked, you headed off with the sole purpose of deramping several stocks I own.
So Buywell, tell me is it:
a) that you're worried about Lipoxen, so deramp other biotechs hoping to scare holders out into your beloved stock
b) you're simply an inconsiderate pr!ck
As I had to last time buywell, I will say this.
Quit posting your silly childish deramping charts and lies on other stocks and I wont feel the need to return here to warn people of the coming cash call here.
And yes, you posted lies, suggesting OXB would need to raise funds soon - when it just has and has a much bigger cash runway than your beloved Lipoxen.
I honestly dont know what you're hoping to acheive.
EVERY time you continue to post provokative deramps on other bio threads, I will return to here and your other stocks to point out the negatives.
I will also repeatedly post this chart below.
Lipoxen needs a deal soon just to avoid a dilutive fundraising.
It has only limited scope for getting a deal.
PRM, OXB and SLN have a longer cash runway than Lipoxen and in the case of PRM and OXB are IMO on the verge of large deals that will cause the share price to double.
YOUR CALL Buywell. You started this silliness by going out of your way to deramp my stocks.|
|123asd: Buywell - All very positive, though in common with other recent RNSs, very much long term.
Since I bought into LPX eight months ago we have had nothing but positive news from the Company, and this has been reflected in the improved share price, at least until recently. However, I sense that, quite apart from the shaky wider market, investors looking at LPX now are keen to know how the Company will fund itself going forward; from reading the published information, it is clear that, with their cash burn, they will shortly require more funding. I know from his own statements that Mr Maguire has been working on precisely this issue in the past few months, in particular commercial deals that will provide an income stream. This of course takes time, what with the legalities etc, hence the relative paucity of news so far this year.
However, I believe we are due, or even overdue, a Prelims statement, and also the AGM should be announced soon, and I am hopeful that we will at the same time get some positive news on the funding front. Maybe that will put an end to the drift lower of the share price in the past couple of months.|
|richardwong78: The bull point from a charting perspective is that not only is the share price in an up trend it is also above the short-term and long-term moving averages. The company is also fundamentally sound. After listening to the CEO's interview with Proactive Investors yesterday I could not resist in investing in this company.|
|richardwong78: If you look at the chart the share price is at the beginning of a breakout. I expect it to go up to at least 20p.|
|duplicate book: Another 11% rise on good volume yet again. Nearly 2.5million traded today. I'm sure there will be a few momentum traders jumping aboard, (or more likely already aboard), but it would be nice for LPX to release news asap to underpin the share price and move us into a higher trading range. So long as its good news of course!! :o))|
|aim_trader: Worth watching again me thinks..
Scott Maguire, CEO of Lipoxen, says it's a mystery why his company's share price is so low
Sunday, October 24, 2010
Scott Maguire, CEO of Lipoxen, tells Proactive Investors why it's a mystery that his company's share price remains so low. He points to strengthened ties with US giant Baxter International plus positive results in trials for the company's influenza and flu treatments as reasons for a bright future.
|duplicate book: bobdown2....we've both been here long enough to know that LPX can retrace just as quick as it can climb! Nice to see the share price rising on relatively little volume this morning. I do think that our seller has now finished, or maybe the market knows that there is something about to be released that will give LPX a bit of a boost?|
|rkhl: Nice find, LPX has got huge potential but I am afraid the market is becoming more and more dominated by investors looking for short term gains which is why the share price is where it is. I also think institutions are wary about supporting small pharma's as they have a mixed track record.
Really good interview and he's right, its all been positive news and I have little doubt that EPO P2 will be good news as well. He won't be drawn on EPO P2 results date though which makes me think it's going to come in very late according to the previous schedule.
I think LPX has got a great future, my only concern being how they fund themselves over the next 4 years. Maybe Baxter will takeover the company.|
"Scott Maguire, CEO of Lipoxen, says it's a mystery why his company's share price is so low
Sunday, October 24, 2010
Scott Maguire, CEO of Lipoxen, tells Proactive Investors why it's a mystery that his company's share price remains so low. He points to strengthened ties with US giant Baxter International plus positive results in trials for the company's influenza and flu treatments as reasons for a bright future."|
Lipoxen share price data is direct from the London Stock Exchange